How stigma surrounding the use of HIV preexposure prophylaxis undermines prevention and pleasure: A call to destigmatize "truvada whores"

American Journal of Public Health

Volumn 105, Issue 10, 2015, Pages 1960-1964

  Calabrese, Sarah K ^a   Underhill, Kristen ^a  

^a YALE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL;

FEMALE; HIV INFECTIONS; HUMAN; MALE; PLEASURE; PRE-EXPOSURE PROPHYLAXIS; SEXUAL BEHAVIOR; SOCIAL STIGMA; STEREOTYPING;

ANTI-HIV AGENTS; EMTRICITABINE, TENOFOVIR DISOPROXIL FUMARATE DRUG COMBINATION; FEMALE; HIV INFECTIONS; HUMANS; MALE; PLEASURE; PRE-EXPOSURE PROPHYLAXIS; SEXUAL BEHAVIOR; SOCIAL STIGMA; STEREOTYPING;

EID: 84941348141     PISSN: 00900036     EISSN: 15410048     Source Type: Journal    
DOI: 10.2105/AJPH.2015.302816     Document Type: Review

References (91)

1. Baeten JM, Donnell D, Ndase P, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012;367(5):399-410
2. Choopanya K, Martin M, Suntharasamai P, et al. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): A randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2013;381(9883):2083-2090
3. Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363(27): 2587-2599
4. Jiang J, Yang X, Ye L, et al. Preexposure prophylaxis for the prevention of HIV infection in high risk populations: A meta-analysis of randomized controlled trials. PLoS One. 2014;9(2):e87674
5. McCormack S, Dunn D. Pragmatic open-label randomised trial of preexposure prophylaxis: the PROUD Study. Talk presented at: Conference on Retroviruses and Opportunistic Infections; February 23-26, 2015; Seattle, WA. Available at: http://www. croiconference. org/sessions/pragmatic-open-labelrandomised-trial-preexposureprophylaxis-proud-study. Accessed April 28, 2015
6. Molina J-M, Capitant C, Charreau I, et al. On demand PrEP with oral TDF-FTC in MSM: results of the ANRS Ipergay Trial. Talk presented at: Conference on Retroviruses and Opportunistic Infections; February 23-26, 2015; Seattle, WA. Available at: http://www. croiconference. org/sessions/demandprep-oral-tdf-ftc-msm-results-anrsipergay-trial. Accessed April 28, 2015
7. Thigpen MC, Kebaabetswe PM, Paxton LA, et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med. 2012;367(5):423-434
8. US Food and Drug Administration. FDA approves first drug for reducing the risk of sexually acquired HIV infection. 2012. Available at: http://www. fda. gov/NewsEvents/Newsroom/ PressAnnouncements/ucm312210. htm. Accessed April 28, 2015
9. Anderson PL, Glidden DV, Liu A, et al. Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men. Sci Transl Med. 2012;4(151):151ra125
10. Donnell D, Baeten JM, Bumpus NN, et al. HIV protective efficacy and correlates of tenofovir blood concentrations in a clinical trial of PrEP for HIV prevention. J Acquir Immune Defic Syndr. 2014;66 (3):340-348
11. Flash CA, Stone VE, Mitty JA, et al. Perspectives on HIV prevention among urban Black women: A potential role for HIV pre-exposure prophylaxis. AIDS Patient Care STDS. 2014;28(12):635-642
12. Wheelock A, Eisingerich AB, Gomez GB, Gray E, Dybul MR, Piot P. Views of policymakers, healthcare workers and NGOs on HIV pre-exposure prophylaxis (PrEP): A multinational qualitative study. BMJ Open. 2012;2(4):pii:e001234
13. Matthews LT, Smit JA, Cu-Uvin S, Cohan D. Antiretrovirals and safer conception for HIV-serodiscordant couples. Curr Opin HIV AIDS. 2012;7(6):569-578
14. Andriote J-M. Spike in tiny number of gay men on PrEP abandoning condoms hardly represents "all" gay men. HuffPost Gay Voices. December 12, 2014. Available at: http://www. huffingtonpost. com/ johnmanuel-andriote/spike-in-tinynumber-of-g-b-6313044. html. Accessed April 28, 2015
15. Myers T. HIV prevention pill will do more harm than good. US News World Rep. August 3, 2012. Available at: http:// www. usnews. com/opinion/articles/ 2012/08/03/hiv-prevention-pill-will-domore-harm-than-good-hiv-pill-will-give-afalse-sense-of-security. Accessed April 28, 2015
16. Weinmeyer RM. Truvada: no substitute for responsible sex. Bioeth Forum. February 14, 2014. Available at: http:// www. thehastingscenter. org/Bioethicsforum/ Post. aspx?id=6777&blogid=140. Accessed April 28, 2015
17. Eaton LA, Kalichman SC. Risk compensation in HIV prevention: implications for vaccines, microbicides, and other biomedical HIV prevention technologies. Curr HIV/AIDS Rep. 2007;4(4):165-172
18. Hogben M, Liddon N. Disinhibition and risk compensation: scope, definitions, and perspective. Sex Transm Dis. 2008;35(12):1009-1010
19. Underhill K. Study designs for identifying risk compensation behavior among users of biomedical HIV prevention technologies: balancing methodological rigor and research ethics. Soc Sci Med. 2013;94:115-123
20. Adams LM, Balderson B, Packett BJ II, Brown K, Catz SL. Providers' perspectives on prescribing pre-exposure prophylaxis (PrEP) for HIV prevention. HIV Specialist. 2015;7(1):18-25
21. Blumenthal J, Jain S, Krakower D, et al. Knowledge is power! Increased provider knowledge scores regarding pre-exposure prophylaxis (PrEP) are associated with higher rates of PrEP prescription and future intent to prescribe PrEP. AIDS Behav. 2015;Epub ahead of print
22. Calabrese SK, Earnshaw VA, Underhill K, Hansen NB, Dovidio JF. The impact of patient race on clinical decisions related to prescribing HIV pre-exposure prophylaxis (PrEP): Assumptions about sexual risk compensation and implications for access. AIDS Behav. 2014;18(2):226-240
23. Karris MY, Beekmann SE, Mehta SR, Anderson CM, Polgreen PM. Are we prepped for preexposure prophylaxis (PrEP)? Provider opinions on the real-world use of PrEP in the United States and Canada. Clin Infect Dis. 2014;58(5):704-712
24. Krakower D, Ware N, Mitty JA, Maloney K, Mayer KH. HIV providers' perceived barriers and facilitators to implementing pre-exposure prophylaxis in care settings: A qualitative study. AIDS Behav. 2014;18(9):1712-1721
25. Lippman SA, Koester KA, Amico KR, et al. Client and provider perspectives on new HIV prevention tools for MSM in the Americas. PLoS One. 2015;10(3): e0121044
26. Puro V, Palummieri A, De Carli G, Piselli P, Ippolito G. Attitude towards antiretroviral pre-exposure prophylaxis (PrEP) prescription among HIV specialists. BMC Infect Dis. 2013;13(1):217
27. Senn H, Wilton J, Sharma M, Fowler S, Tan D. Knowledge of and opinions on HIV pre-exposure prophylaxis among front-line service providers at Canadian AIDS service organizations. AIDS Res Hum Retroviruses. 2013;29(9):1183-1189
28. Tang EC, Sobieszczyk ME, Shu E, Gonzales P, Sanchez J, Lama JR. Provider attitudes toward oral preexposure prophylaxis for HIV prevention among high-risk men who have sex with men in Lima, Peru. AIDS Res Hum Retroviruses. 2014;30(5):416-424
29. Tellalian D, Maznavi K, Bredeek UF, Hardy WD. Pre-exposure prophylaxis (PrEP) for HIV infection: results of a survey of HIV healthcare providers evaluating their knowledge, attitudes, and prescribing practices. AIDS Patient Care STDS. 2013;27(10):553-559
30. Tripathi A, Ogbuanu C, Monger M, Gibson JJ, Duffus WA. Preexposure prophylaxis for HIV infection: healthcare providers' knowledge, perception, and willingness to adopt future implementation in the southern US. South Med J. 2012;105(4):199-206
31. White JM, Mimiaga MJ, Krakower DS, Mayer KH. Evolution of Massachusetts physician attitudes, knowledge, and experience regarding the use of antiretrovirals for HIV prevention. AIDS Patient Care STDS. 2012;26(7): 395-405
32. Belluz J. The Truvada wars. BMJ. 2014;348:g3811
33. Crary D. Truvada, HIV prevention drug, divides gay community. Huffington Post. April 7, 2014. Available at: http:// www. huffingtonpost. com/2014/04/07/ truvada-gay-men-hiv-n-5102515. html. Accessed April 28, 2015
34. Duran D. Truvada whores? Huff-Post Gay Voices. November 12, 2012. Available at: http://www. huffingtonpost. com/david-duran/truvada-whores-b- 2113588. html. Accessed April 28, 2015
35. Healy P. A lion still roars, with gratitude: Larry Kramer lives to see his "Normal Heart" filmed for TV. New York Times. May 21, 2014. Available at: http://www. nytimes. com/2014/05/ 25/arts/television/larry-kramer-livesto-see-his-normal-heart-filmed-for-tv. html?-r=0. Accessed April 28, 2015
36. Berlin M. OUT100: Zachary Quinto: Artist of the year. OUT. November 11, 2014. Available at: http://www. out. com/ out-exclusives/out100-2014/2014/11/ 11/out100-zachary-quinto-artist-year. Accessed April 28, 2015
37. Barro J. AIDS group wages lonely fight against pill to prevent HIV. New York Times. November 16, 2014. Available at: http://www. nytimes. com/2014/11/17/ upshot/aids-group-wages-lonely-fightagainst-pill-to-prevent-hiv. html?abt= 0002&abg=0. Accessed April 28, 2015
38. Grant RM, Anderson PL, McMahan V, et al. Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: A cohort study. Lancet Infect Dis. 2014;14(9):820-829
39. Guest G, Shattuck D, Johnson L, et al. Changes in sexual risk behavior among participants in a PrEP HIV prevention trial. Sex Transm Dis. 2008;35(12):1002-1008
40. Hosek SG, Siberry G, Bell M, et al. Project PrEPare (ATN082): the acceptability and feasibility of an HIV preexposure prophylaxis (PrEP) trial with young men who have sex with men (YMSM). J Acquir Immune Defic Syndr. 2013;62(4):447-456
41. Liu AY, Vittinghoff E, Chillag K, et al. Sexual risk behavior among HIV-uninfected men who have sex with men participating in a tenofovir preexposure prophylaxis randomized trial in the United States. J Acquir Immune Defic Syndr. 2013;64(1):87-94
42. Marcus JL, Glidden DV, Mayer KH, et al. No evidence of sexual risk compensation in the iPrEx trial of daily oral HIV preexposure prophylaxis. PLoS One. 2013;8(12):e81997
43. Minnis AM, Gandham S, Richardson BA, et al. Adherence and acceptability in MTN 001: A randomized cross-over trial of daily oral and topical tenofovir for HIV prevention in women. AIDS Behav. 2013;17(2):737-747
44. Mugwanya KK, Donnell D, Celum C, et al. Sexual behaviour of heterosexual men and women receiving antiretroviral pre-exposure prophylaxis for HIV prevention: A longitudinal analysis. Lancet Infect Dis. 2013;13(12):1021-1028
45. Van Damme L, Corneli A, Ahmed K, et al. Preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2012;367(5):411-422
46. Hojilla JC, Koester KA, Cohen SE, et al. Sexual behavior, risk compensation and HIV prevention strategies among participants in the San Francisco Demonstration Project: A qualitative analysis of counseling notes. AIDS Behav. 2015; Epub ahead of print
47. Ryan B. 45% of PrEP users at SF clinic report using condoms less often. AIDSMEDS. December 10, 2014. Available at: http://www. aidsmeds. com/ articles/PrEP-condoms-less-1667- 26573. shtml. Accessed April 28, 2015
48. Al-Tayyib AA, Thrun MW, Haukoos JS, Walls NE. Knowledge of pre-exposure prophylaxis (PrEP) for HIV prevention among men who have sex with men in Denver, Colarado. AIDS Behav. 2014; 18(suppl 3):340-347
49. Bil JP, Davidovich U, van der Veldt WM, et al. What do Dutch MSM think of preexposure prophylaxis to prevent HIV infection? A cross-sectional study. AIDS. 2015;29(8):955-964
50. Brooks RA, Landovitz RJ, Kaplan RL, Lieber E, Lee SJ, Barkley TW. Sexual risk behaviors and acceptability of HIV pre-exposure prophylaxis among HIVnegative gay and bisexual men in serodiscordant relationships: A mixed methods study. AIDS Patient Care STDS. 2012;26(2):87-94
51. Corneli A, Field S, Namey E, et al. Preparing for the rollout of pre-exposure prophylaxis (PrEP): A vignette survey to identify intended sexual behaviors among women in Kenya and South Africa if using PrEP. PLoS One. 2015;10(6):e0129177
52. Galea JT, Kinsler JJ, Salazar X, et al. Acceptability of pre-exposure prophylaxis as an HIV prevention strategy: barriers and facilitators to pre-exposure prophylaxis uptake among at-risk Peruvian populations. Int J STD AIDS. 2011;22 (5):256-262
53. Grov C, Whitfield THF, Rendina HJ, Ventuneac A, Parsons JT. Willingness to take PrEP and potential for risk compensation among highly sexually active gay and bisexual men. AIDS Behav. 2015; Epub ahead of print
54. Golub SA, Kowalczyk W, Weinberger CL, Parsons JT. Preexposure prophylaxis and predicted condom use among high-risk men who have sex with men. J Acquir Immune Defic Syndr. 2010;54(5):548-555
55. Hoff CC, Chakravarty D, Bircher AE, et al. Attitudes towards PrEP and anticipated condom use among concordant HIV-negative and HIV-discordant male couples. AIDS Patient Care STDS. 2015; Epub ahead of print
56. Holt M, Murphy DA, Callander D, et al. Willingness to use HIV pre-exposure prophylaxis and the likelihood of decreased condom use are both associated with unprotected anal intercourse and the perceived likelihood of becoming HIV positive among Australian gay and bisexual men. Sex Transm Infect. 2012;88 (4):258-263
57. Kubicek K, Arauz-Cuadra C, Kipke MD. Attitudes and perceptions of biomedical HIV prevention methods: voices from young men who have sex with men. Arch Sex Behav. 2015;44(2):487-497
58. Lorente N, Fugon L, Carrieri MP, Andreo C, Le Gall J-M, Cook E. Acceptability of "on-demand" pre-exposure HIV prophylaxis trial among men who have sex with men living in France. AIDS Care. 2012;24(4):468-477
59. Smith DK, Toledo L, Smith DJ, Adams MA, Rothenberg R. Attitudes and program preferences of African-American urban young adults about pre-exposure prophylaxis (PrEP). AIDS Educ Prev. 2012;24(5):408-421
60. Underhill K, Morrow KM, Kuo C, et al. PrEP acceptability, access and predicted user behaviors in US male sex workers: implications for effectiveness. Talk presented at: American Public Health Association 142nd Annual Meeting; November 15-19, 2014; New Orleans, LA. Available at: https://apha. confex. com/apha/142am/webprogram/ Paper311677. html. Accessed April 28, 2015
61. Golub SA, Operario D, Gorbach PM. Pre-exposure prophylaxis state of the science: empirical analogies for research and implementation. Curr HIV/AIDS Rep. 2010;7(4):201-209
62. Auerbach JD, Kinsky S, Brown G, Vignetta C. Knowledge, attitudes, and likelihood of pre-exposure prophylaxis (PrEP) use among US women at risk of acquiring HIV. AIDS Patient Care STDS. 2015;29(2):102-110
63. Brooks RA, Kaplan RL, Lieber E, Landovitz RJ, Lee SJ, Leibowitz AA. Motivators, concerns, and barriers to adoption of preexposure prophylaxis for HIV prevention among gay and bisexual men in HIV-serodiscordant male relationships. AIDS Care. 2011;23(9):1136-1145
64. Nodin N, Caarballo-Diéguez A, Ventuneac AM, Balan IC, Remien R. Knowledge and acceptability of alternative HIV prevention bio-medical products among MSM who bareback. AIDS Care. 2008;20(1):106-115
65. Pérez-Figueroa RE, Kapadia F, Barton SC, Eddy JA, Halkitis PN. Acceptability of PrEP uptake among racially/ ethnically diverse young men who have sex with men: the P18 Study. AIDS Educ Prev. 2015;27(2):112-125
66. Saberi P, Gamarel KE, Neilands TB, Comfort M, Sheon N, Darbes LA. Ambiguity, ambivalence, and apprehensions of taking HIV-1 pre-exposure prophylaxis among male couples in San Francisco: A mixed methods study. PLoS One. 2012;7(11):e50061
67. Koester K, Amico KR, Liu A, et al. Sex on PrEP: qualitative findings from the iPrEx open label extension (OLE) in the US. Talk presented at: XX International AIDS Conference; July 20-25, 2014; Melbourne, Australia. Available at: http://pag. aids2014. org/Abstracts. aspx? AID=10815. Accessed April 28, 2015
68. Underhill K. Identifying and addressing risk compensation in ARVbased HIV prevention. Talk presented at: XX International AIDS Conference; July 20-25, 2014; Melbourne, Australia. Available at: http://pag. aids2014. org/ session. aspx?s=2020#5. Accessed April 28, 2015
69. Desai K, Sansom SL, Ackers ML, et al. Modeling the impact of HIV chemoprophylaxis strategies among men who have sex with men in the United States: HIV infections prevented and costeffectiveness. AIDS. 2008;22(14):1829-1839
70. Verguet S, Stalcup M, Walsh JA. Where to deploy pre-exposure prophylaxis (PrEP) in sub-Saharan Africa? Sex Transm Infect. 2013;89(8):628-634
71. Liu A, Cohen S, Follansbee S, et al. Early experiences implementing preexposure prophylaxis (PrEP) for HIV prevention in San Francisco. PLoS Med. 2014;11(3):e1001613
72. Gallagher T, Link L, Ramos M, Bottger E, Aberg J, Daskalakis D. Selfperception of HIV risk and candidacy for pre-exposure prophylaxis among men who have sex with men testing for HIV at commercial sex venues in New York City. LGBT Health. 2014;1(3):218-224
73. Horberg M, Raymond B. Financial policy issues for HIV pre-exposure prophylaxis: cost and access to insurance. Am J Prev Med. 2013;44(1, suppl 2):S125-S128
74. Hedlund J. Risky business: safety regulations, risk compensation, and individual behavior. Inj Prev. 2000;6(2):82-90
75. Wilde GJS. Target Risk 2: A New Psychology of Safety and Health. Toronto, ON: PDE Publications; 2001
76. Blumenthal J, Haubrich RH. Will risk compensation accompany preexposure prophylaxis for HIV? Virtual Mentor. 2014;16(11):909-915
77. Underhill K. Risk-taking and rulemaking: Addressing risk compensation behavior through FDA regulation of prescription drugs. Yale J Regul. 2013; 30(2):377-437
78. Smith DK, Herbst JH, Rose CE. Estimating HIV protective effects of method adherence with combinations of preexposure prophylaxis and condom use among African American men who have sex with men. Sex Transm Dis. 2015;42 (2):88-92
79. Grey JA, Rothenberg R, Sullivan PS, Rosenberg ES. Racial differences in the accuracy of perceived partner HIV status among men who have sex with men (MSM) in Atlanta, Georgia. J Int Assoc Provid AIDS Care. 2015;14(1):26-32
80. Minnis AM, Steiner MJ, Gallo MF, et al. Biomarker validation of reports of recent sexual activity: results of a randomized controlled study in Zimbabwe. Am J Epidemiol. 2009;170(7):918-924
81. Marcus JL, Buisker T, Horvath T, et al. Helping our patients take HIV pre-exposure prophylaxis (PrEP): A systematic review of adherence interventions. HIV Med. 2014;15(7):385-395
82. Underhill K. Intimacy, condom use, and pre-exposure prophylaxis (PrEP) acceptability among men who have sex with men (MSM) in primary partnerships: A comment on Gamarel and Golub. Ann Behav Med. 2015;49(2):151-153
83. Fortenberry JD. The evolving sexual health paradigm: transforming definitions into sexual health practices. AIDS. 2013;27(suppl 1):S127-S133
84. Tolman DL, Striepe MI, Harmon T. Gender matters: constructing a model of adolescent sexual health. J Sex Res. 2003;40(1):4-12
85. Crosby R, Yarber WL, Sanders SA, Graham CA. Condom discomfort and associated problems with their use among university students. J Am Coll Health. 2005;54(3):143-147
86. Greene GJ, Andrews R, Kuper L, Mustanski B. Intimacy, monogamy, and condom problems drive unprotected sex among young men in serious relationships with other men: A mixed methods dyadic study. Arch Sex Behav. 2014;43(1):73-87
87. Sanders SA, YarberWL, Kaufman EL, Crosby RA, Graham CA, Milhausen RR. Condom use errors and problems: A global view. Sex Health. 2012;9(1):81-95
88. Gamarel KE, Golub SA. Intimacy motivations and pre-exposure prophylaxis (PrEP) adoption intentions among HIV-negative men who have sex with men (MSM) in romantic relationships. Ann Behav Med. 2015;49(2):177-186
89. Golub SA, Radix A, Hilley A, Catalanotti A, Marazzo S. Developing and implementing a PrEP demonstration/ implementation hybrid in a communitybased health center. Talk presented at: 9th International Conference on HIV Treatment and Prevention Adherence; June 8-10, 2014; Miami, FL. Available at: http://www. iapac. org/ AdherenceConference/presentations/ ADH9-OA409. pdf. Accessed April 28, 2015
90. Shucart B. What PrEP means for people living with HIV. Frontiers Media. January 7, 2014. Available at: http:// www. imstilljosh. com/lgbtprep/op-edwhat-prep-means-for-people-living-withhiv. Accessed April 28, 2015
91. World Health Organization. Constitution of the World Health Organization. 1946. Available at: http://www. who. int/ governance/eb/who-constitution-en. pdf. Accessed April 28, 2015.